GEN Exclusives

More »

GEN News Highlights

More »
Mar 21, 2007

BioLineRx In-Licenses Anti-Inflammatory Peptide

  • BioLineRx obtained a novel peptide for the treatment of inflammatory diseases from Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd.

    "We believe that BL-4020 offers the potential for a highly effective and safe therapy utilizing a novel mechanism of action," remarks Morris C. Laster, M.D., CEO of BioLineRx.

    BL-4020 is a peptide designed to function as an anti-inflammatory agent in various diseases, such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis. ManLAM has been shown to modulate the function of the immune system and suppress various inflammatory diseases.

    BioLineRx expects that BL-4020, which retains the anti-inflammatory properties of ManLAM, will be effective with low toxicity. In preclinical trials, it was shown to be effective in a wide variety of animal models of inflammation, according to the company.

    The worldwide, exclusive license agreement with Yissum and Ramot includes the development and commercialization of BL-4020.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?